Literature DB >> 3338492

Thrombospondin binding by human squamous carcinoma and melanoma cells: relationship to biological activity.

B L Riser1, J Varani, K O'Rourke, V M Dixit.   

Abstract

Human squamous carcinoma cells attach and spread on thrombospondin (TSP)-coated culture dishes but exhibit significant variability among individual cell lines in their degree of responsiveness. Using a highly responsive squamous carcinoma line and a cell line which is much less responsive (as well as a human melanoma cell line which does not respond at all in the adhesion assay), we have examined binding of exogenous radiolabeled TSP. The cells which were the most responsive to TSP in the adhesion assay bound the greatest amount of radiolabeled ligand. Binding was time- and dose-dependent, saturable, inhibitable with excess unlabeled TSP, reversible, and specific. The less-responsive squamous carcinoma cells bound only 25-30% of the amount of TSP bound by the highly responsive cells while the nonresponsive melanoma cells bound less than 10% of the amount bound by the highly responsive squamous carcinoma cells. Our previous studies (J. Varani et al. (1986) Exp. Cell Res. 167, 376) have shown that the highly responsive squamous carcinoma cells also synthesized the greatest amount of TSP as indicated by biosynthetic labeling studies. The less-responsive squamous carcinoma cells were intermediate in synthetic activity and no synthetic activity was seen with the melanoma cells. These findings suggest that the amount of ligand bound may determine the degree of biological responsiveness and that endogenously synthesized TSP may be the source of that ligand.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3338492     DOI: 10.1016/0014-4827(88)90303-5

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  10 in total

Review 1.  Thrombospondin as a mediator of cancer cell adhesion in metastasis.

Authors:  D A Walz
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 2.  Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast.

Authors:  A Rice; C M Quinn
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

3.  Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.

Authors:  M Streit; P Velasco; L F Brown; M Skobe; L Richard; L Riccardi; J Lawler; M Detmar
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

4.  Thrombospondin-induced adhesion of human platelets.

Authors:  G P Tuszynski; M A Kowalska
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

5.  Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1.

Authors:  S A Kim; S J Um; J H Kang; K J Hong
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

6.  Characterization of thrombospondin synthesis, secretion and cell surface expression by human tumor cells.

Authors:  J Varani; B L Riser; L A Hughes; T E Carey; S E Fligiel; V M Dixit
Journal:  Clin Exp Metastasis       Date:  1989 May-Jun       Impact factor: 5.150

7.  Angiogenesis in Paget's Disease of the Vulva and the Breast: Correlation with Microvessel Density.

Authors:  Patricia E Ellis; Allan B Maclean; L F Wong Te Fong; Julie C Crow; Christopher W Perrett
Journal:  J Oncol       Date:  2012-03-26       Impact factor: 4.375

8.  Matrix-bound thrombospondin promotes angiogenesis in vitro.

Authors:  R F Nicosia; G P Tuszynski
Journal:  J Cell Biol       Date:  1994-01       Impact factor: 10.539

9.  Thrombospondin modulates focal adhesions in endothelial cells.

Authors:  J E Murphy-Ullrich; M Höök
Journal:  J Cell Biol       Date:  1989-09       Impact factor: 10.539

10.  Thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo.

Authors:  H Boukerche; O Berthier-Vergnes; E Tabone; M Bailly; J F Doré; J L McGregor
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.